Stamulumab

Stamulumab (also known as MYO-029) is an experimental myostatin inhibiting drug developed for the treatment of muscular dystrophy (MD). Stamulumab was developed by Wyeth Pharmaceuticals, which was later acquired by Pfizer.

History[edit | edit source]

Stamulumab was first developed by Wyeth Pharmaceuticals in the early 2000s. The drug was part of a new class of treatments for MD that aimed to inhibit the production of myostatin, a protein that inhibits muscle growth. The idea was that by blocking myostatin, Stamulumab could help increase muscle mass and strength in people with MD.

Mechanism of Action[edit | edit source]

Stamulumab is a monoclonal antibody that binds to myostatin and prevents it from binding to its receptor. This inhibits the signal that myostatin sends to muscle cells to stop growing, allowing the muscle cells to grow and multiply more than they would normally.

Clinical Trials[edit | edit source]

Stamulumab has undergone several clinical trials to test its safety and efficacy. In a Phase I trial, the drug was found to be safe and well-tolerated. However, in a Phase II trial, the drug did not meet its primary endpoint of improving muscle strength. Despite this, some participants did see improvements in muscle mass and function, suggesting that the drug may still have potential for treating MD.

Current Status[edit | edit source]

As of 2021, Stamulumab is not currently approved for use by any health regulatory authority. Pfizer, which acquired Wyeth in 2009, has not announced any plans to continue development of the drug.